| Jefferies LLC 520 Madison Avenue New York, NY 10022 |
Leerink Partners, LLC 299 Park Avenue, 21st Floor New York, NY 10171 |
June 18, 2018
| Re: | Xeris Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration File No. 333-225191 |
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Dear Sir/Madam:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933 (the “Act”), we, as representatives of the several Underwriters, wish to advise you that 371 copies of the Preliminary Prospectus included in the Registration Statement on Form S-1 were distributed during the period June 11, 2018 through the date hereof, to prospective underwriters, institutions, dealers and others.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934.
In accordance with Rule 461 of the Act, we hereby join in the request of Xeris Pharmaceuticals, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:00 p.m. Eastern time on June 20, 2018, or as soon thereafter as practicable.
[Remainder of page intentionally left blank]
| Very truly yours, | ||
| By: |
JEFFERIES LLC | |
| By: |
/s/ Charlie Glazer | |
| Name: Charlie Glazer | ||
| Title: US Head of Equity Syndicate | ||
| By: |
LEERINK PARTNERS, LLC | |
| By: |
/s/ Byron T. Webster | |
| Name: Byron T. Webster | ||
| Title: Managing Director | ||
[Signature page to Acceleration Request Letter]
-2-